Analysis-Prices for New US Drugs Rose 35% in 2023, More Than the Previous Year

Pharmaceutical companies last year launched new U.S. drugs at prices 35% higher than in 2022, reflecting in part the industry's embrace of expensive therapies for rare...

Related Keywords

United States ,Boston ,Massachusetts ,Cuba ,Cuban ,Americans ,Dan Ollendorf ,Dana Goldman ,Regeneron Veopoz ,Brian Connelly ,Health Policy Economics ,Institute For Clinical ,Reuters ,Schaeffer Center ,Drug Administration ,Boston Consulting Group ,Economic Review ,Mark Cuban ,Cost Plus Drugs ,Health Policy ,Reduction Act ,Consulting Group ,Bill Berkrot ,Biologic Therapy ,Iologics ,Drug Costs ,Drug Cost ,Medication Costs ,Drug Price ,Drug Pricing ,Medication Price ,Edication Pricing ,Genomics Genomic Medicine ,Rare Diseases ,Muscular Dystrophy ,Gene Therapy ,Covid 19 ,019 Novel Coronavirus ,019 Ncov ,Uhan Coronavirus ,Uman Coronavirus Hku1 ,Uman Coronavirus Oc43 ,Cov Oc43 ,Uman Coronavirus 229e ,Cov 229e ,Corona Virus ,Ovid19 ,